The European Medicines Agency’s human medicines committee (CHMP) has recommended granting a marketing authorization in the EU for Rybelsus (semaglutide) for the treatment of adults with insufficiently controlled Type 2 diabetes to improve glycaemic control as an adjunct to diet and exercise. It is the first glucagon-like peptide (GLP-1) receptor agonist treatment (a class of non-insulin medicines for people with type 2 diabetes) developed for oral use, providing patients with another option to treat the disease without injections. The opinion adopted by the CHMP is an intermediary step on Rybelsus’s path to patient access.
Menu
